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The growth of solid tumours and the formation of metastases
depend on the formation of new blood vessels (Folkman, 1994).
Angiogenesis is a complex multistep process involving extracellular
matrix remodelling, endothelial cell migration and proliferation, and
capillary differentiation and anastomosis, all of which are regulated
by angiogenic peptides (Blood and Zetter, 1990). Vascular density
has been shown to be an independent prognostic marker in several
types of human tumours, including breast carcinoma (Weidner et al,
1992; Im et al, 1997). Vascular endothelial growth factor (VEGF,
also known as vascular permeability factor) is a strong endothelial
cell mitogen that increases the permeability of microvessels
(Dvorak et al, 1995). The effects of VEGF are mediated through 2
distinct high-affinity endothelial cell surface receptors, flt-1 and
KDR/Flk-1, both of which are type III tyrosine kinase receptors
(Shibuya, 1995). Increased expression of VEGF has been reported
in several types of human tumours and has been shown to correlate
with poor prognosis (Takahashi et al, 1995; Toi et al, 1995). In
animal models, antisense VEGF and monoclonal antibody to VEGF
inhibited VEGF expression and tumour growth (Kim et al, 1993;
Asano et al, 1995; Cheng et al, 1996; Saleh et al, 1996). 
Several reasons exist to suggest that gene therapy should be
considered as a strategy to suppress the neovascularization of solid
tumours. First, local, intratumoral gene therapy can reduce the
risk of widespread antiangiogenesis resulting from systemic
administration of an antiangiogenic agent. Second, gene transfer
can lead to a local accumulation of the antiangiogenic protein.
Third, current technology does not allow genes to be transferred to
all of the target cells that are relevant to the growth of the tumour;
however, antiangiogenic gene therapy does not require that genes
be transferred to all target cells. Increasing knowledge of the mole-
cular basis of cancer has yielded several potential therapies, but
the clinical application of these methods has not been completely
successful, in part because the in vitro models used for screening
often do not duplicate in vivo conditions. To overcome this limita-
tion, we developed an adenovirally mediated antisense-VEGF
vector, Ad5CMV-aVEGF, that could be used to down-regulate
VEGF secretion and thereby inhibit tumour growth in vivo. We
previously found that transfecting the U87-MG glioma cell line
with this vector down-regulated VEGF165 mRNA and VEGF
protein secretion compared with cells that had been transfected
with Ad5(dl312) (Im et al, 1999). The purpose of the present study
was to test whether treating MDA231-MB human breast cancer
xenografts with the Ad5CMV-aVEGF vector would reduce the
expression of VEGF protein and suppress tumour formation
through antiangiogenesis mechanism in an experimental model of
breast cancer. 
MATERIALS AND METHODS 
Construction and generation of the adenoviral vectors 
To down-regulate endogenous VEGF expression and enhance
the in vivo applicability of the antisense VEGF strategy, we
constructed a replication-deficient recombinant adenoviral vector
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containing the cDNA for VEGF165 in an antisense orientation
(Figure 1) as described previously (Zhang et al, 1993). Briefly, the
574-bp VEGF cDNA was cloned by using the pCRII vector
(Invitrogen, Carlsbad, CA) and sequenced by using the T7
promoter and M13 reverse primers. Then, the VEGF cDNA was
extracted from the pCRII vector with HindIII and Not I restriction
enzymes and inserted in an antisense orientation into the E1-
deleted expression plasmid pXCL-cytomegalovirus (CMV)
shuttle vector (a generous gift from Dr WW Zhang, Urogen Corp,
San Diego, California, USA) between the CMV promoter and
SV40 polyadenylation signal site to create the expression plasmid
pXCL-CMV-aVEGF. This plasmid was cotransfected with
plasmid PJM17 into the transformed human embryonic kidney cell
line 293 (American Type Culture Collection, Manassas, VA) by
the calcium phosphate method. Homologous recombination of the
expression plasmid and pJM17 in 293 cells replaced the E1 region
with the expression cassette from the expression plasmid. Then
individual viral plaques were isolated, and plaques containing the
human VEGF165 cDNA were identified by polymerase chain reac-
tion (PCR) and restriction enzyme digestion and then amplified in
293 cells. Ad5(dl312), an E1-deleted adenovirus type 5 carrying
no exogenous gene, was used as an adenoviral control vector
(Jones and Shenk, 1979). Ad5CMV-aVEGF, Ad5(dl312), and
Ad5CMV-bgal were propagated in 293 cells and then purified on a
cesium chloride gradient. The preparations were then dialysed and
stored in dialysis buffer (10 mmolL–1 Tris-HCl and 1 mmol–1
MgCl2, pH 7.4) with 10% glycerol at –80˚C. The titre of each viral
stock was determined in 293 cells by plaque assay (Graham and
Prevec, 1991). 
Infection conditions 
Cell lines were infected as described previously (Gomez-Manzano
et al, 1996). Briefly, cells were infected by diluting the viral stock
to a specified concentration, adding the dilution to cell mono-
layers, and incubating the cells at 37˚C for 30 min with brief agita-
tion every 5 min. After this, culture medium containing 10%
serum was added, and the infected cells were returned to the 37˚C
incubator. Control cells were infected with the Ad5(dl312) or
mock-infected with culture medium. Ad5CMV-bgal, an aden-
ovirus type 5-based vector that lacks E1 and contains the CMV
promoter that drives the Escherichia coli LacZ gene coding for
the b-galactosidase protein, was used to verify the efficiency of
infection. 
Cell line and tissue culture conditions 
The human breast cancer cell line MDA231-MB was obtained
from the American Type Culture Collection. MDA231-MB cells
were maintained in DMEM/F-12 medium (1:1, vol:vol) supple-
mented with 10% fetal bovine serum in a humidified atmosphere
containing 5% CO2 at 37˚C. The 293 cells were maintained in
high-glucose DMEM with 10% heat-inactivated fetal bovine
serum. 
Transduction efficiency 
To verify the transduction efficiency of the Ad5 vector, we
infected MDA231-MB cells (105 cells per well) with Ad5CMV-
bgal at multiplicities of infection (MOI) (the ratio of the number of
infectious virions to the number of susceptible cells) ranging from
25 to 200. 48 hours later, cells were fixed with 4% paraformalde-
hyde in a phosphate-buffered NaCl solution, and then stained with
1 mg ml–1 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside in 5
mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2
mM MgCl2 in phosphate-buffered NaCl solution at 37˚C
overnight. The efficiency of infection (the percentage of b-galac-
tosidase-positive cells) was determined by the number of blue
cells among 500 cells on triplicate dishes. 
Enzyme-linked immunosorbent assay (ELISA) 
To quantify human secretory VEGF165 in conditioned medium, we
used ELISA according to the manufacturer’s protocol (R & D
Systems, Minneapolis, MN). To prepare the conditioned medium,
cells were seeded overnight (105 cells per well) with medium
containing 10% serum and then infected with either Ad5CMV-a
VEGF or Ad5(dl312) at different MOI. Culture medium was used
for the mock-infection condition. Triplicate dishes of cells
subjected to each treatment were used. Conditioned media were
processed 5 days after infection as follows. 30 hours before 
media collection, the cells were washed 3 times with 2 ml
of serum-free medium and then incubated with 2 ml of serum-free
medium per well for 6 h, after which the medium was aspirated
and the cells were washed again with 2 ml of serum-free medium
per well and incubated for 24 hours in 1 ml of medium containing
2% serum. The medium was collected in a tube containing 1 ml of
100 mM phenylmethylsulphonyl fluoride. 
Cell growth rate in vitro 
MDA231-MB cells were seeded at a density of 104 cells per well
in six-well culture plates and allowed to adhere overnight. The
next day, the cells were infected with 100 MOI of Ad5CMV-
aVEGF or Ad5(dl312) or with culture medium. Triplicate dishes
of each treatment were counted at regular intervals until the 12th
day after infection. 
Ad5CMV-aVEGF treatment in vivo 
Animal experiments were carried out in the animal facility of The
University of Texas MD Anderson Cancer Center in accordance
with institutional guidelines. For these experiments, athymic female
nu/nu mice, 4–6 weeks of age, were acclimated and caged in groups
of 5 or fewer. All mice were fed a diet of animal chow and water ad
libitum. The animals were anaesthetized with methoxyflurane
before all procedures and were observed until full recovery. To
create xenograft tumours, MDA231-MB cells (5 ´ 106 in 100 ml of
serum-free medium) were injected s.c. into the mammary fat pads
of the mice. Beginning 4 days after tumour-cell implantation,
tumours were treated by intratumoral injection of 5 ´ 108 plaque-
forming units (PFU) of either Ad5(dl312) or Ad5CMV-aVEGF (8
mice/group) every other day for a total of 4 times; 3 of these 4-dose
treatment cycles were conducted at 4-week intervals. Tumour
volume was calculated from weekly caliper measurements of the
largest (a) and smallest (b) diameters of each tumour using the
formula a ´ b2 ´ 0.4 (Attia and Weiss, 1966). 
Immunohistochemical analysis and microvessel
counting 
At the end of the 130-day measurement period, the mice were killed1254 S-A Im et al 
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with CO2, and their tumours were excised and fixed in neutral-
buffered formalin for routine histologic examination and immuno-
histochemical staining. Tumours were analysed with an anti-VEGF
mAb (PharMingen, San Diego, CA) to see the expression of VEGF
and with an anti-CD31 mouse mAb (Biogenix, San Ramon, CA) to
count microvessels as follows. Each paraffin block was serially
sectioned at 4 mm intervals, dewaxed, and heated in a microwave for
10 min to retrieve antigen. Endogenous peroxidase in the histologic
sections was removed by incubation with 3% hydrogen peroxide in
water for 15 min at room temperature. The primary antibodies were
diluted 1:200 (VEGF) or 1:10 (anti-CD31) in phosphate-buffered
saline with 0.5% bovine serum albumin, and the dilutions were
added to the sections and incubated either for 1 h at room tempera-
ture (VEGF) or overnight (CD31). The bound antibodies were
detected by the avidin-biotin-peroxidase method and visualized with
3-amino-9-ethylcarbazole (AEC). Cellular nuclei were counter-
stained blue with haematoxylin. 
The areas containing the greatest numbers of microvessels or
tumour ‘hot spots’ were identified by scanning the stained sections
at low magnification (40 ´ and 100 ´) with a light microscope.
Once these areas were identified, individual stained microvessels
were point-counted at 200 ´ magnification with a square grid that
corresponded to a field size of 0.68 mm2. Large microvessels and
any single brown-stained endothelial cells that were clearly sepa-
rate from other microvessels were included in the microvessel
count; branching structures were counted as 1 vessel unless there
was a break in the continuity of the vessel, in which case it was
counted as 2 distinct vessels. The mean number of microvessels
from 3 fields was used for analysis. 
Statistical analysis 
All values were expressed as means ± standard deviations.
Unpaired t-tests were used to evaluate differences in tumour
volumes in the different treatment groups. A P value of less than
0.05 was considered to be statistically significant. 
RESULTS 
Adenovirus-mediated gene transfer in MDA231-MB cells 
We assessed the efficiency of gene transfer via the replication-defi-
cient recombinant adenoviral vector Ad5CMV-aVEGF, which
contains the cDNA for VEGF165 in an antisense orientation (Figure
1), in the MDA231-MB breast cancer cell line by measuring
reporter gene expression 48 h after cells were infected with
Ad5CMV-bgal at different MOI. The transduction efficiency ranged
from 8.3 ±2.05% at 25 MOI to 89.4 ±3.30% at 200 MOI (Figure 2). 
VEGF expression and cell growth after treatment with
Ad5CMV-a VEGF in vitro 
We used ELISA to determine the amount of secretory VEGF protein
in conditioned medium collected 5 days after MDA231-MB cells
has been mock-infected or infected with Ad5(dl312) or Ad5CMV-
aVEGF. The mock-infected MDA231-MB cells secreted VEGF
protein at a concentration of 110.98 ±13.63 pg ml–1 105cells–1 24 h–1;
cells infected with Ad5(dl1312) produced 105.73 ± 10.03 pg ml–1
105 cells–1 24 h–1. In contrast, cells infected with 100 MOI of
Ad5CMV-aVEGF produced 73.24 ± 7.02 pg ml–1 105 cells–1 24 h–1
Ad5 E1
CMV promoter aVEGF165 SV 40 pA
ATG codon 574 bp
Figure 1 Structure of the recombinant adenoviral vector Ad5CMV-aVEGF.
The entire vector is shown at top, and an enlargement of human antisense-
VEGF expression cassette is shown at bottom. The expression cassette
contains human CMV promoter, human VEGF165 cDNA (574 bp) in an
antisense orientation, and the SV40 polyadenylation (pA) signal 
0
0
20
40
60
80
100
25 50 75 100 125 150 175 200
%
 
P
o
s
i
t
i
v
e
 
c
e
l
l
s
MOI
Figure 2 Ad5CMV-bgal transduction efficiency in MDA231-MB breast
cancer cells. Cells were infected with Ad5CMV-bgal at the MOI values
shown. The percentage of blue cells were determined by counting the
number of blue cells among 500 cells on each of 2 dishes, then dividing this
number by 500 and multiplying by 100. The results shown are the means
from triplicate experiments 
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Figure 3 VEGF protein production. MDA231-MB cells were infected with
Ad5(d1312) or Ad5CMV-aVEGF, and conditioned medium collected 5 days
later was subjected to ELISA. Error bars indicate SD from 3 replicate
experiments Antisense VEGF inhibits breast cancer growth 1255
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(Figure 3). Transfecting cells with 200 MOI of Ad5CMV-aVEGF
reduced the amount of VEGF protein to 62.35 ± 8.24 pg ml–1 105
cells–1 24 h–1. 
Despite the reduction in endogenous VEGF protein secretion by
Ad5CMV-aVEGF-infected MDA231-MB cells, the growth rate
of these cells was not different from that of mock-or Ad5(dl312)-
infected MDA231-MB cells (Figure 4). 
Xenograft tumour growth after treatment with Ad5CMV-
aVEGF 
To determine the effectiveness of Ad5CMV-aVEGF therapy in vivo,
we treated mice that had been implanted with MDA231-MB cells
with periodic intratumoral injections of Ad5(dl312) or Ad5CMV-
aVEGF (8 mice/group). 4 months after the treatment began
(2 months after the final injection), the mean tumour size in the
Ad5(dl312) treatment group was 335.23 ± 83.98 mm3; mean tumour
size in the Ad5CMV-aVEGF treatment group was 67.85 ± 34.65
mm3 (P = 0.0005) (Figure 5). In addition to this direct evidence of an
antitumor effect, Ad5CMV-aVEGF produced no adverse effects on
gross observation of the health and behaviour of the mice. 
VEGF expression and microvessel count in tumours 
Immunohistochemical analysis of tumour tissue that had been
treated with Ad5(dl312) showed substantial VEGF protein expres-
sion in the diffuse pattern expected of a secreted protein. In
contrast, little immunoreactivity was detected in the Ad5CMV-
aVEGF-treated tumours (Figure 6). To determine whether the
reduction in VEGF secretion and the inhibition of tumour growth
were associated with a reduction in the ability of the cells to induce
neovascularization, we assessed blood vessel density in tumour
tissue by immunostaining the specimens with a monoclonal anti-
body against the endothelial cell surface protein marker CD31.
Fewer microvessels were found in tumours treated with Ad5CMV-
aVEGF (12.9 ± 1.85 per field) than in tumours treated with
Ad5(dl312) (41.0 ± 6.72 per field) (P = 0.03). 
DISCUSSION 
The purpose of this study was to describe the in vitro and in vivo
effect of Ad5CMV-aVEGF, a replication-deficient recombinant
adenoviral vector carrying antisense human VEGF165, in breast
cancer. Our results showed that the transfer of antisense VEGF
cDNA in vitro efficiently down-regulated the secretion of VEGF
protein, both in vitro and in an experimental model of breast cancer. 
VEGF is a potent endothelial cell mitogen and positive effector
of angiogenesis. VEGF is known to be up-regulated in many
tumour types (Kim et al, 1993; Asano et al, 1995; Cheng et al,
1996; Saleh et al, 1996; Im et al, 1997). In one study, VEGF RNA
expression was significantly elevated in breast cancer specimens
relative to that in samples of adjacent non-neoplastic tissue,
whereas expression of bFGF, TGF-a and TGF-b RNA in tumour
tissues was variable (Yoshiji et al, 1996). Up-regulation of VEGF
in breast tumour specimens has been correlated with poor prog-
nosis (Weidner et al, 1992; Toi et al, 1995). VEGF was shown in 1
study to be critical for the initial subcutaneous tumour growth of
T-47D breast carcinoma cells, whereas other angiogenic factors
could compensate for the loss of VEGF after the tumours reached
a certain size (Yoshiji et al, 1997). 
Our results, and those of others, suggest that targeting the
endothelial cells of a tumour with antiangiogenic molecules can be
an effective antitumor strategy. In one study, transfecting VEGF
cDNA into xenografted C6 rat glioma cells produced hypervascu-
larization of the tumour with abnormally large vessels; the abrupt
withdrawal of VEGF resulted in regression of these vessels (Saleh et
al, 1996). On the other hand, treating tumours with monoclonal anti-
bodies specific to VEGF decreased or completely inhibited their
neovascularization (Kim et al, 1993). Inhibition of endogenous
VEGF expression by using an antisense VEGF sequence reduced
vascularization and drastically suppressed the tumorigenicity of
cancer cell lines (Saleh et al, 1996). We previously found that VEGF
could be down-regulated in glioma cells by using ribozymes
designed to target the VEGF sequence (Ke et al, 1998). In the
present study, Ad5CMV-aVEGF did not affect the growth of the
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Figure 4 Growth curves for MDA231-MB cells that were mock-infected or
infected with 100 MOI of Ad5(d1312) or Ad5CMV-a VEGF. Cells were
seeded at a density of 104 cells per well and allowed to grow under standard
culture conditions for 12 days. The cells were counted using a
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Figure 5 Growth rates of subcutaneous tumours in nude mice treated with
intratumoral injections of 5 ´ 108 PFU Ad5(dl312) (n = 8) or Ad5CMV-aVEGF
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4 weeks starting 4 days after tumour-cell implantation. Tumour volumes were
calculated from caliper measurements and are presented as the mean ±
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tumour cells in vitro, but significantly suppressed the growth of
tumour xenografts and reduced the levels of VEGF protein in vivo,
a finding consistent with the apparent anticancer effects of other
angiogenesis inhibitors (Beohm et al, 1997; Tanaka et al, 1998). 
The results of our work suggest that anti-sense therapy targeting
VEGF may have clinical implications for breast cancer treatment.
However, several issues remain to be addressed, and some of them
cannot be examined using currently available animal models. The
host range of human adenoviruses is restricted, and no appropriate
animal models exist to allow further exploration of the effectiveness
of adenoviral vectors in immune-competent animal models. In a real-
istic scenario, intratumoral administration of the adenovirus in cancer
patients, particularly after multiple treatments, may result in the
production of neutralizing antibodies with subsequent elimination of
infected cells. However, additional virus-induced cytotoxic effect
might be beneficial. Thus, an immune response directed against viral
antigens might augment tumour killing by affecting non-infected
tumour cells. In addition, the intratumoral recruitment and stimula-
tion of tumour-specific T lymphocytes theoretically could lead, in
some cases, to systemic anti-tumor immunity. 
In summary, we found adenovirus-mediated transfer of an anti-
sense-VEGF gene to be an efficient means of delivering the gene to
breast cancer cells in vitro and in vivo. Moreover, this successful
delivery of the gene effectively decreased endogenous VEGF levels
and suppressed the growth of tumours derived from human breast
cancer MDA231-MB cells. These findings underscore the pivotal
role of the VEGF system in breast tumour angiogenesis, and suggest
that the Ad5CMV-aVEGF vector may be a useful tool for thera-
peutic targeting of the tumour vasculature in breast cancer. 
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